MentalHealthDaily

Antidepressants & Iron Pathways: Targeting Ferroptosis to Treat Depression (2023 Review)

Depression, a debilitating mental disorder, stands as a significant challenge to global health, potentially becoming the leading cause of disability worldwide. Recent research has unearthed a promising connection between ferroptosis, a newly discovered form of cell death, and the onset of depression, offering fresh avenues for developing innovative antidepressant therapies. Traditional Chinese Medicine (TCM) and …

SSRI-Induced Sexual Dysfunction Reversed with “Drug Holidays” on Weekends (2024 Study)

by GLOOM

Selective serotonin reuptake inhibitors (SSRIs) are a mainstay in the treatment of various mental disorders but often come with the unwelcome side effect of sexual dysfunction. This issue can significantly affect patients’ adherence to their medication regime, often leading to treatment discontinuation. A recent clinical trial offers a new perspective, suggesting that ‘drug holidays’ – …

Pharmacogenomics (PGx) for Depression: Genetic Analysis to Amplify Antidepressant Efficacy? (2023 Review)

by GLOOM

Depression, a leading cause of disability globally, often presents challenges in treatment due to the variability in individual responses to antidepressants. Pharmacogenomic (PGx) testing, an approach aligning treatment with genetic makeup, promises to tailor depression therapy more effectively. Highlights: Major Depressive Disorder (MDD) impacts a significant portion of the global population, with traditional treatments often …

Antidepressants & Dementia Risk in Elderly Users: SSRIs vs. TCAs (2024 Study)

by GLOOM

Recent research has uncovered connections between the use of antidepressants and the risk of developing dementia in the elderly. This complex relationship, marked by varying results and considerations, is becoming a critical area of study in geriatric medicine and mental health. In light of these findings, it is crucial to delve into the nuances of …

Psychedelics for Depression: Targeting the 5-HT2A Receptor & Beyond (2023 Study)

by GLOOM

The quest for effective treatments for Major Depressive Disorder (MDD) has taken a revolutionary turn with the exploration of psychedelic compounds. Recent research has evaluated the potential of substances like psilocybin and lisuride, offering new hope for patients unresponsive to traditional antidepressants. Highlights: Traditional Limitations: Standard antidepressants often fail to provide relief for 30% of …

Lateral Habenula & Depression: The Anti-Reward Center (Mechanisms & Antidepressant Treatments)

by GLOOM

Depression is a complex and multifaceted disorder affecting millions worldwide. Emerging evidence suggests the lateral habenula, a small brain region, plays a crucial role in depression’s development and persistence. By influencing neurotransmitter systems and interacting with stress pathways, the lateral habenula’s dysfunction may lead to the classic symptoms of depression. Highlights: The lateral habenula is …

Polyphenols & Depression: Antidepressant Potential of Plant Compounds

by GLOOM

Depression, a prevalent and debilitating mental health condition, affects millions worldwide. Recent studies have shown an intriguing link between dietary polyphenols, naturally occurring compounds in plant-based foods, and depression outcomes. Highlights: Prevalence of Depression: More than 300 million people globally suffer from depression, marking it as a leading cause of disability. Role of Polyphenols: Polyphenols, …